Brian Piekos Sells 1,767 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CFO Brian Piekos sold 1,767 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $27,512.19. Following the transaction, the chief financial officer directly owned 13,762 shares of the company’s stock, valued at $214,274.34. This represents a 11.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV opened at $15.76 on Thursday. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The company has a 50-day moving average of $15.49 and a 200-day moving average of $13.95. The company has a market capitalization of $796.67 million, a price-to-earnings ratio of -3.99 and a beta of -0.19. KalVista Pharmaceuticals, Inc. has a 52 week low of $9.23 and a 52 week high of $19.00.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently modified their holdings of KALV. BNP Paribas Financial Markets raised its position in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $55,000. Wolverine Asset Management LLC bought a new position in KalVista Pharmaceuticals during the third quarter worth about $57,000. KLP Kapitalforvaltning AS bought a new stake in KalVista Pharmaceuticals in the third quarter valued at approximately $63,000. Finally, Truvestments Capital LLC lifted its position in shares of KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after buying an additional 3,360 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Needham & Company LLC boosted their price target on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Citizens Jmp lowered their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Tuesday, November 11th. Finally, Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, KalVista Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $29.40.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.